Skip to content
The People's CodeSearch
Menu

S. 483 · Senate bill · 119th Congress

Responsibility in Drug Advertising Act of 2025

  1. Introduced
  2. In committeeHealth, Education, Labor, and Pensions
  3. Passed the Senate (not yet)
  4. Passed the House (not yet)
  5. Law (not yet)

What it would change

About this text

Text: , (the only version so far)

Official text on Congress.gov

This bill would change existing law, but we couldn't automatically match its changes to the Code.

Its own words follow, each change we couldn't place marked where it stands.

3 changes we couldn't place in the Code
  • The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) is amended— — we can't yet read how this change is worded In the bill’s text
  • in section 301 (21 U.S.C. 331), by adding at the end the following:(jjj) The conduct of direct-to-consumer advertising of a drug in violation of section 506M.; and — it changes a law that isn't arranged into the US Code, or doesn't say where in the Code In the bill’s text
  • in chapter V, by inserting after section 506L (21 U.S.C. 356l) the following:506M. Direct-to-consumer drug advertising (a) Prohibitions.— (1) First 3 years.— (A) In general.— Subject to subparagraph ( — we can't yet make this kind of change, such as adding a whole new section In the bill’s text

Sec. 1. Short title This Act may be cited as the Responsibility in Drug Advertising Act of 2025.

Sec. 2. Direct-to-consumer drug advertising The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) is amended—

We couldn't place this change in the Code: we can't yet read how this change is worded.

(1) in section 301 (21 U.S.C. 331), by adding at the end the following:

(jjj) The conduct of direct-to-consumer advertising of a drug in violation of section 506M.

; and

We couldn't place this change in the Code: it changes a law that isn't arranged into the US Code, or doesn't say where in the Code.

(2) in chapter V, by inserting after section 506L (21 U.S.C. 356l) the following:

506M. Direct-to-consumer drug advertising

(a) Prohibitions.—

(1) First 3 years.—

(A) In general.— Subject to subparagraph (B), no person shall conduct direct-to-consumer advertising, including on a social media platform, of a drug approved under section 505(c) before the end of the 3-year period beginning on the date of such approval.

(B) Waiver.— The Secretary may waive the application of subparagraph (A) to a drug during the third year of the 3-year period described in such subparagraph if—

(i) the sponsor of the drug submits an application to the Secretary pursuant to subparagraph (C); and

(ii) the Secretary, after considering the application and any accompanying materials, determines that direct-to-consumer advertising of the drug would have an affirmative value to public health.

(C) Application for waiver.— To seek a waiver under subparagraph (B), the sponsor of a drug shall submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may require.

(2) Subsequent years.— The Secretary may prohibit direct-to-consumer advertising, including on social media platforms, of a drug during the period beginning at the end of the 3-year period described in paragraph (1)(A) if the Secretary determines that the drug has significant adverse health effects based on post-approval studies, risk-benefit analyses, adverse event reports, the scientific literature, any clinical or observational studies, or any other appropriate resource.

(b) Regulations.— Not later than 1 year after the date of the enactment of this section, the Secretary shall revise the regulations promulgated under this Act governing drug advertisements to the extent necessary to implement this section.

(c) Rule of construction.— This section shall not be construed to diminish the authority of the Secretary to prohibit or regulate direct-to-consumer advertising of drugs, including on social media platforms, under any other provision of law.

(d) Effective date.— This section applies only with respect to a drug approved under section 505(c) on or after the date that is 1 year before the date of enactment of this section.

.

We couldn't place this change in the Code: we can't yet make this kind of change, such as adding a whole new section.